← Back to patent-cliff list
Norfloxacin Lactate
Tier C — Watch / tradeNorfloxacin Lactate
-
Originator
1996
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Topoisomerase IV, Bacterial DNA gyrase
Indications (approved)：Cystitis, Pneumonia, Respiratory tract infection, Acute bronchitis, Chronic bronchitis, Urinary tract infection, 伤寒, Pyelonephritis
Regional status
US
-
EU
-
China
Approved
1996-01-01
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Norfloxacin Lactate?
Approved indications include: Cystitis, Pneumonia, Respiratory tract infection, Acute bronchitis, Chronic bronchitis, Urinary tract infection, 伤寒, Pyelonephritis.
When does the Norfloxacin Lactate patent expire?
No public expiry year is available for Norfloxacin Lactate yet; this page updates once verified.
How do I get a quote for Norfloxacin Lactate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-04